Cargando…
Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats
BACKGROUND: Avascular necrosis of bone (osteonecrosis) can cause structural failure and subsequent deformation, leading to joint dysfunction and pain. Structural failure is the result of resorption of necrotic bone during revascularization, before new bone has formed or consolidated enough for loadb...
Autores principales: | Åstrand, Jörgen, Aspenberg, Per |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126216/ https://www.ncbi.nlm.nih.gov/pubmed/12165099 http://dx.doi.org/10.1186/1471-2474-3-19 |
Ejemplares similares
-
Systemic zoledronate treatment both prevents resorption of allograft bone and increases the retention of new formed bone during revascularization and remodelling. A bone chamber study in rats
por: Åstrand, Jörgen, et al.
Publicado: (2006) -
Combined Pharmacotherapy with Alendronate and Desferoxamine Regulate the Bone Resorption and Bone Regeneration for Preventing Glucocorticoids-Induced Osteonecrosis of the Femoral Head
por: Sheng, Hongfeng, et al.
Publicado: (2020) -
Fluid pressure and flow as a cause of bone resorption
por: Fahlgren, Anna, et al.
Publicado: (2010) -
The Bone Resorption Inhibitors Odanacatib and Alendronate Affect Post-Osteoclastic Events Differently in Ovariectomized Rabbits
por: Jensen, Pia Rosgaard, et al.
Publicado: (2013) -
Impregnation of bone chips with alendronate and cefazolin, combined with demineralized bone matrix: a bone chamber study in goats
por: Mathijssen, Nina MC, et al.
Publicado: (2012)